Search clinical trials for: Anti-VEGF

Total 87467 results

Johns Hopkins University

Terminated

Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

Wet Macular Degeneration | Neovascular Age-related Macular Degeneration | Submacular Hemorrhage

United States
University of Leipzig

Unknown

Influence of Systemic Parameters in Diabetic Macular Edema - LIPSIA Study

Diabetic Macular Edema | Macular Edema | Retinal Vein Occlusion

Germany
University of California, Davis
University of California, San Francisco

Completed

ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD) (PBAMD2)

Exudative Age-related Macular Degeneration

United States
Groupe Hospitalier Pitie-Salpetriere

Completed

Evaluation of Reporting of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors Associated Cardiovascular Adverse reactioN. (VEGAN)

Vascular Diseases | Cardiac Complication

France
Shahid Beheshti University of Medical Sciences

Completed

Pain and Visual Outcome in Intravitreal Bevacizumab Injection (pain & visual)

Diabetic Macular Edema

Iran, Islamic Republic of
Peking University Third Hospital

Recruiting

Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR Patients

Proliferative Diabetic Retinopathy

China
Ruijin Hospital

Completed

A Study on the Treatment Strategy of NVG Secondary to PDR

Proliferative Diabetic Retinopathy | Neovascular Glaucoma

China
Centre Hospitalier Sud Francilien

Completed

Improve Screening Criteria for Retinopathy of Prematurity in Two French Center (DEREP3)

Retinopathy of Prematurity

France
Wenzhou Medical University

Unknown

Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy

Proliferative Diabetic Retinopathy | Vitrectomy | PRP | Anti-VEGF
Bayer

Completed

Non-Persistence/Non-Adherence (NP/NA) in Wet Age-related Macular Degeneration (wAMD) Patients in Germany

Wet Macular Degeneration

Germany
Eyetech Pharmaceuticals

Completed

Phase II/III Study of Anti-VEGF in Neovascular AMD

Macular Degeneration | Choroidal Neovascularization

United States
Maisonneuve-Rosemont Hospital
Novartis; Foundation Fighting Blindness; Fonds de recherche en ophtalmologie... and other collaborators

Completed

Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD

Exudative Age Related Macular Degeneration

Canada
Wenzhou Medical University

Unknown

Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage

Vitrectomy | Branch Retinal Vein Occlusion | Anti-VEGF
Northwestern University

Completed

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

Neurofibromatosis Type 1 | Neurofibromatosis Type 2 | Adult Ependymoma | Recurrent Adult Brain Tumor | Acoustic Schwannoma | Adult Anaplastic Meningioma | Adult Grade I Meningioma | Adult Grade II Meningioma | Adult Meningeal Hemangiopericytoma | Adult Papillary Meningioma

United States
Peking University Third Hospital

Recruiting

Effects of Anti-VEGF Targeted Drugs on Patients' Blood Pressure and Endothelial Function

Endothelial Dysfunction | Cardiac Toxicity | VEGF

China
Case Comprehensive Cancer Center
National Cancer Institute (NCI); NovoCure Ltd.

Completed

NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States
Semmelweis University

Completed

Seven-year Outcomes Following Intensive Anti-VEGF Therapy in Wet AMD

Age-Related Macular Degeneration

Hungary
Losordo, Douglas, M.D.

Completed

VEGF Gene Transfer for Diabetic Neuropathy

Diabetic Neuropathy

United States
Beijing Hospital

Not yet recruiting

Study on the Biomarkers of Anti-VEGF Treatment for Choroidal Neovascularization

Choroidal Neovascularization
Medical University of Vienna

Recruiting

Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting

Exudative Macular Degeneration

Austria
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma

United States, Taiwan, Australia
Pfizer

Terminated

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

Gastrointestinal Tumors | Esophageal Adenocarcinomas | Colorectal Adenocarcinomas | Gastric Adenocarcinomas

United States, Australia, Japan
Roswell Park Cancer Institute
GlaxoSmithKline

Active, not recruiting

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
Sensimed AG

Terminated

TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection

Open Angle Glaucoma | Neovascular Age Related Macular Degeneration (AMD)

Spain
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Recurrent Adult Brain Neoplasm

United States
Second Affiliated Hospital of Nanchang University
Nanchang University

Unknown

Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis (OWONBNSCLCLM)

Non-small Cell Lung Cancer | EGFR Activating Mutation | Leptomeningeal Metastasis
Case Comprehensive Cancer Center

Completed

Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy

Prostate Cancer

United States
Chang Gung Memorial Hospital

Enrolling by invitation

The Analysis of Association of Retinopathy of Prematurity, Gut Microbiome Profile, and Systemic Inflammation

Retinopathy of Prematurity | Microbiome

Taiwan
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

Malignant Ovarian Epithelial Tumor | Ovarian Gynandroblastoma | Ovarian Sertoli-Leydig Cell Tumor | Ovarian Sex Cord Tumor With Annular Tubules | Ovarian Steroid Cell Tumor | Ovarian Granulosa Cell Tumor | Ovarian Sex Cord-Stromal Tumor | Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell...

United States
Northwestern University
National Cancer Institute (NCI); NovoCure Ltd.

Recruiting

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Atypical Meningioma | Grade III Meningioma | Recurrent Meningioma | Anaplastic (Malignant) Meningioma | Grade II Meningioma | Supratentorial Meningioma

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma | Stage III Skin Melanoma

United States
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor (S0502)

Gastrointestinal Stromal Tumor

United States, Canada
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma

United States
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
University of Aarhus

Recruiting

Dysregulated Urea-synthesis at Terminal Uremia

Urea Cycle Disorder | Uremia

Denmark
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI); PTC Therapeutics

Completed

PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors

Brain and Central Nervous System Tumors

United States
Rigshospitalet, Denmark

Completed

The Effect of Mobilized Stem Cell by G-CSF and VEGF Gene Therapy in Patients With Stable Severe Angina Pectoris

Ischemic Heart Disease

Denmark
Ophthotech Corporation

Terminated

Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD

Age-related Macular Degeneration

United States
National Cancer Institute (NCI)

Completed

Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Solid Neoplasm

United States
Losordo, Douglas, M.D.

Completed

VEGF Gene Transfer for Critical Limb Ischemia

Ischemia | Leg Ulcer | Critical Limb Ischemia

United States
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Young Patients With Refractory Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)
Fox Chase Cancer Center

Completed

Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma (Mel47)

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma

United States
Seoul National University Bundang Hospital

Unknown

"Stop Early Age-related Macular Degeneration (AMD) From Vision Loss Eternally" Study (SAVE)

Age-Related Macular Degeneration | Retinal Drusen

Korea, Republic of
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Endometrial Carcinoma

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Cervical Squamous Cell Carcinoma | Recurrent Cervical Cancer

United States
Barbara Ann Karmanos Cancer Institute
Genentech, Inc.

Completed

Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)

Completed

S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Anaplastic Large Cell Lymphoma

United States
Universidad Católica San Antonio de Murcia

Completed

Safety Analysis of Chronic Intake of a β-alanine Supplement (HIPOX-β)

Product Safety

Spain
National Cancer Institute (NCI)

Completed

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States

Search clinical trials for: Anti-VEGF

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations